187 related articles for article (PubMed ID: 23928514)
1. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
[TBL] [Abstract][Full Text] [Related]
2. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
[TBL] [Abstract][Full Text] [Related]
4. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.
Mercado-Pimentel ME; Miller C; Rolph DN; Villalobos EF; Dunn AM; Mohan PM; Igarashi S; Liu X; Yrun-Duffy M; Patel NK; Read CM; Francis RH; Lane AI; Murugesh S; Jacob A
Otol Neurotol; 2017 Jan; 38(1):139-146. PubMed ID: 27755359
[TBL] [Abstract][Full Text] [Related]
7. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
8. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
9. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
10. Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells.
Wang J; Lv P
Bioengineered; 2021 Dec; 12(1):755-762. PubMed ID: 33622177
[TBL] [Abstract][Full Text] [Related]
11. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
Burns SS; Chang LS
Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
[TBL] [Abstract][Full Text] [Related]
12. Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.
Curic S; Wu Y; Shan B; Schaaf C; Utpadel D; Lange M; Kuhlen D; Perone MJ; Arzt E; Stalla GK; Renner U
J Neurooncol; 2013 Jul; 113(3):385-96. PubMed ID: 23666203
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
[TBL] [Abstract][Full Text] [Related]
14. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
Johnson MD; O'Connell MJ; Walter K
BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
[TBL] [Abstract][Full Text] [Related]
16. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
[TBL] [Abstract][Full Text] [Related]
17. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
18. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
[TBL] [Abstract][Full Text] [Related]
19. [Effects of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells].
Liu T; Zhang M; Deng Y; Zhang H; Sun C; Yang X; Ji W
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 May; 22(9):403-7. PubMed ID: 18652313
[TBL] [Abstract][Full Text] [Related]
20. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
